Kodiak Sciences

Update in progress

KOD (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on therapies for retinal diseases. Its lead candidate, tarcocimab tedromer (KSI-301), is an anti-VEGF antibody biopolymer in Phase 3 for retinal vascular diseases, including diabetic retinopathy, wet AMD, retinal vein occlusion, and diabetic macular edema. Preclinical programs include KSI-501 (IL-6 and VEGF-trap bispecific) and KSI-101 (KSI-501P) for retinal inflammation. Formerly Oligasis, renamed in 2015. Based in Palo Alto, CA.

Company score

Sentiment: 0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.31; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive